Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Acute myeloid leukemia clinical practice guidelines in oncologyMargaret R O'Donnell, Frederick R Appelbaum, Maria R Baer, et al.
Haematologica|April 1, 2026
<i>Erratum</i> to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial"Richard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Biomarker Research|March 17, 2023
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patientsEra L Pogosova-Agadjanyan, Xing Hua, Megan Othus, et al.
Blood Advances|October 6, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trialMark J Levis, Harry P Erba, Pau Montesinos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Acute myeloid leukemiaMargaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Acute myeloid leukemia clinical practice guidelines in oncologyMargaret R O'Donnell, Frederick R Appelbaum, Maria R Baer, et al.
Haematologica|April 1, 2026
<i>Erratum</i> to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial"Richard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Biomarker Research|March 17, 2023
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patientsEra L Pogosova-Agadjanyan, Xing Hua, Megan Othus, et al.
Blood Advances|October 6, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trialMark J Levis, Harry P Erba, Pau Montesinos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Acute myeloid leukemiaMargaret R O'Donnell, Frederick R Appelbaum, Steven E Coutre, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Pageof 17